Welcome to our dedicated page for MiNK Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on MiNK Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company dedicated to developing cutting-edge therapies for treating cancer and other immune-mediated diseases. The company's core focus lies in pioneering allogeneic invariant natural killer T (iNKT) cell therapies, which are designed to be off-the-shelf solutions, making them readily available for patients in need.
MiNK's flagship program, agenT-797, is currently in a Phase 2 trial aimed at treating second-line gastroesophageal cancer. This trial, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center, builds on promising results from earlier studies where agenT-797 demonstrated the ability to overcome resistance to immune checkpoint inhibitors. The trial is exploring the combination of agenT-797 with other advanced treatments, such as botensilimab and balstilimab, to improve outcomes for patients with challenging gastrointestinal cancers.
Another significant candidate in MiNK's pipeline is MiNK-215, an IL-15 armored FAP-targeting CAR iNKT cell therapy. This candidate has shown remarkable efficacy in preclinical models for colorectal cancer liver metastases, overcoming the immune barriers typically posed by liver metastases.
The company recently reported a strong year-end financial position with ongoing collaborations, including a research agreement with ImmunoScape. MiNK Therapeutics continues to advance its clinical programs while maintaining a focus on scalable and reproducible manufacturing processes for its iNKT cell therapies.
Founded and headquartered in New York, NY, MiNK Therapeutics remains committed to delivering innovative and effective treatments for life-threatening diseases. For more information, visit their website or follow them on social media at @MiNK_iNKT.
MiNK Therapeutics, a clinical-stage biopharmaceutical company specializing in allogeneic iNKT cell therapies for cancer and immune-mediated diseases, will attend the BTIG 2022 Biotechnology Conference. The company will participate virtually and conduct one-on-one meetings with investors on August 8th and 9th. MiNK is advancing both native and engineered iNKT programs, focusing on scalable and reproducible manufacturing for off-the-shelf delivery. For more details, visit their website at minktherapeutics.com.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will announce its Q2 2022 financial results prior to the market opening on August 9, 2022. A conference call is scheduled for 11:00 a.m. ET on the same day to discuss the results and provide corporate updates. MiNK specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases, with a focus on scalable and reproducible manufacturing.
MiNK Therapeutics, a biopharmaceutical company focusing on allogeneic invariant natural killer T (iNKT) cell therapies, announced its virtual Annual Meeting of Shareholders set for June 8, 2022, at 5:00 PM ET. Shareholders can join via a dedicated website using a control number from proxy materials, while guests can listen without a control number. The company aims to advance its pipeline of iNKT programs targeting cancer and immune-mediated diseases, with scalable and reproducible manufacturing processes.
MiNK Therapeutics announced its Q1 2022 results, reporting a cash balance of $34.7 million and a projected 2022 cash burn of $16.8 million. The company is progressing well with its clinical programs, including agenT-797 studies for solid tumors and multiple myeloma, aiming for data readouts in 2H 2022. They launched an in-house GMP manufacturing process targeting 10,000 doses/year and advanced their pipeline with IND enabling studies for BCMA-CAR-iNKT.
However, net losses for Q1 were $7.8 million, up from $3.8 million in Q1 2021, driven by increased clinical activities.
MiNK Therapeutics, a clinical-stage biopharmaceutical company focused on iNKT cell therapies for cancer and immune-mediated diseases, will announce its Q1 2022 financial results and business update on May 10, 2022, before market opens. The disclosure will be made via press release and available on the company's investor website. MiNK is advancing a pipeline of native and next-generation engineered iNKT therapies, aiming for scalable off-the-shelf delivery.
MiNK Therapeutics (NASDAQ: INKT) is advancing its allogeneic invariant natural killer T (iNKT) cell therapies, particularly AgenT-797, in ongoing clinical trials for solid tumors and COVID-19 related ARDS, showing a remarkable 75% survival rate in treated patients. No lymphodepletion or serious side effects such as cytokine release syndrome have been reported. The company completed a $46 million IPO and recorded a cash burn of approximately $13 million in 2021, with a cash balance of $39 million as of year-end. MiNK plans to manufacture over 10,000 doses of iNKT cells annually to support its clinical programs.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will announce its fourth quarter and full year 2021 financial results and business update on March 18, 2022. The company specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The financial report will be accessible via a press release and the investor section of the company's website. MiNK's pipeline includes native and engineered iNKT programs aimed at scalable manufacturing and off-the-shelf delivery.
MiNK Therapeutics has initiated a Phase 1 clinical trial for AgenT-797, targeting patients with solid tumor cancers. The therapy can be dosed up to 1 billion cells without lymphodepletion, showing no signs of cytokine release syndrome or neurotoxicity. Clinical trials are also being conducted for multiple myeloma and viral ARDS. Preliminary results indicate a favorable safety profile and promising early clinical activity, especially when combined with approved anti-PD-1 checkpoint inhibitors. The company is focused on developing allogeneic iNKT cell therapies for cancer treatment.
MiNK Therapeutics announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27, 2022, at 12:00 PM ET. The event will discuss the company's advancements in iNKT cell therapies aimed at treating cancer and immune-mediated diseases. Investors can access the live presentation and a replay through MiNK's website after the event.
MiNK is focused on developing scalable iNKT cell therapies, enhancing treatment options in oncology.
MiNK Therapeutics announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat hosted by Evercore on December 1, 2021, at 8:25 AM ET. This event will focus on the company's innovative allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases. Interested parties can register for the event online, and a replay will be available afterward on the MiNK website.
For further details about MiNK Therapeutics and its clinical-stage developments, visit their official website.
FAQ
What is the current stock price of MiNK Therapeutics (INKT)?
What is the market cap of MiNK Therapeutics (INKT)?
What does MiNK Therapeutics specialize in?
What is agenT-797?
What are the recent achievements of MiNK Therapeutics?
Where is MiNK Therapeutics headquartered?
What partnerships has MiNK Therapeutics established?
What is MiNK-215?
How does MiNK Therapeutics deliver their therapies?
How can investors get more information about MiNK Therapeutics?
What is the primary focus of MiNK Therapeutics' current research?
How does agenT-797 work?
